Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts.

Aderans Research Institute primarily operates in the Biotechnical Research, Commercial business / industry within the Engineering, Accounting, Research, and Management Services sector. This organization has been operating for approximately 14 years. Aderans Research Institute is estimated to generate $4.3 million in annual revenues, and employs approximately 53 people at this single location.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Smith & Nephew PLC designs, manufactures and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is a sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Tissue Regenix was established in May 2006, to commercialize innovative technologies in regenerative medicine. The underpinning science was developed over the last decade in the world-leading Institute for Medical and Biological Engineering at the University of Leeds by Professors John Fisher and Eileen Ingham. The research has received in excess of £4 million grant funding to date from UK research councils (EPSRC, BBSRC) and the Children's Heart Surgery Fund.\nThe business has exclusive rights over several platform technologies in regenerative tissue engineering. Tissue Regenix is led by a team of highly experienced medical device industry veterans with a strong track record of translating early developmental work into products that are currently benefitting patients worldwide in a range of clinical settings from heart valves to orthopedic implants.\nTissue Regenix is focused on delivering its lead product, the dCELL Vascular Patch, into the clinic. Follow on products include the dCELL Meniscus, as well as an extensive pipeline of other product offerings in the vascular, cardiac and orthopedic areas.\nThe company is committed to pursuing the highest standards of product safety and quality and has retained world-class independent advisors to ensure the dCELL range meets or exceeds these.

Cytograft Tissue Engineering, Inc. engages in the development of cardiovascular medicine. It offers novel cell-based therapies to repair and rebuild diseased tissues and organ without using synthetic biomaterials. The company was founded by Todd N. McAllister and Nicolas L'Heureux in 2000 and is headquartered in Novato, CA.

Cytex Therapeutics, Inc. is an American private company. The firm develops bio-artificial devices to treat osteoarthritis and musculoskeletal diseases.\nThe company says this about itself: Cytex is a Durham, NC-based private company developing patented products that restore cartilage in arthritic joints. Founded by Drs. Guilak, Estes and Moutos, Cytex plans to conduct First in Human pilot studies later this year in patients diagnosed with femoroacetabular impingement, or FAI, a disorder affecting younger adults and a common cause of hip pain. Cytex is planning studies in additional indications where cartilage damage is part of the clinical picture such as arthritis in the ankle and knee.

Calcitec, Inc. provides biomaterial solutions. It develops synthetic bone substitutes optimized for orthopedic and neurosurgical applications. The company is headquartered in Austin, TX.

Tengion, Inc. is an American development-stage regenerative medicine company founded in 2003 with financing from J&J Development Corporation, HealthCap and Oak Investment Partners, which is headquartered in Winston-Salem, North Carolina. Its goals are discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues, to address unmet medical needs in urologic, renal, gastrointestinal, and vascular diseases and disorders. The company creates these human neo-organs from a patient’s own cells or autologous cells, in conjunction with its Organ Regeneration Platform. The company declared Chapter 7 bankruptcy in December 2014, and it, along with its assets and tissue engineering samples, have been bought back by its creditors and former executives as of March 2015. The purchase was expedited, so that time-sensitive research can continue.

IsoTis NV manufactures, markets and sells a range of bone graft substitutes and other related medical devices. These devices are used to enhance the repair and regeneration of bone in spinal and trauma surgery, joint replacements and dental applications. IsoTis' products are primarily used spinal fusion, trauma, joint revision, bone void filling and iliac crest backfills procedures. The company is headquartered in Bilthoven, the Netherlands

Nortis is a biotech company that has developed tissue-engineering techniques and organ-on-a-chip systems for the creation of a human micro-tissue environment within small, disposable, microfluidic chips. The company's technology enables living models of human organs that will drastically accelerate the discovery and introduction of new therapies and alleviate the use of lab animals. By growing tissue from human organ systems inside small microfluidic chips, researchers and assay developers can conduct in-vitro testing directly on functional human tissues. Nortis was founded in 2012 and is headquartered in Woodinville, Washington.

Organogenesis Inc. is a regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell based product (Apligraf®, approved for the treatment of venous leg ulcers). Apligraf is now the leading regenerative medicine product in the world, with two FDA-approved indications. In 2012 we received an FDA approval for GINTUIT™, a living, human cell-based product that represents a new therapeutic class in dentistry.

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.